Kineret (Anakinra) - Summary

KINERET SUMMARY

Kineret® (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). Kineret® differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus.

Kineret® is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents (see WARNINGS).

KINERET NEWS HIGHLIGHTS

Media Articles Related to Kineret (Anakinra)

Preclinical Findings Highlight Novel Approach To Maximizing DsiRNAs In Rheumatoid Arthritis; Data Appear Published By Molecular Therapy
Source: Arthritis / Rheumatology News From Medical News Today [2008.10.03]

Rheumatoid arthritis tied to joint surgery in past (Reuters)
Source: Y! Health Arthritis News [2008.10.02]

Arana Files IND For Lead Anti-Inflammatory Product ART621 In Rheumatoid Arthritis (RA) Indication
Source: Arthritis / Rheumatology News From Medical News Today [2008.10.01]

Follow-On Phase I Study For Novel Oral Anti-Inflammatory Drug Targeting Rheumatoid Arthritis And Type 1 Diabetes
Source: Arthritis / Rheumatology News From Medical News Today [2008.10.01]

Working Environment Is One Cause Of Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2008.09.25]

more>>

Published Studies Related to Kineret (Anakinra)

Safety of extended treatment with anakinra in patients with rheumatoid arthritis. [2006.08]

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. [2004.09]

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. [2004.06]

Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. [2004.06]

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. [2004.05]

more>>

Clinical Trials Related to Kineret (Anakinra)

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria [Completed]

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) [Completed]

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire [Completed]

Anti-Inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes [Enrolling by invitation]

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma [Active, not recruiting]

more>>